Aurinia Pharmaceuticals (AUPH) Assets Average (2017 - 2026)

Aurinia Pharmaceuticals' Assets Average history runs 9 years deep, the most recent figure standing at $737.8 million for Q1 2026.

• Quarterly Assets Average rose 39.8% year-over-year to $737.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $737.8 million (up 39.8% YoY) and the FY2025 annual result came in at $651.1 million, up 18.52% from the prior year.
• Assets Average was $737.8 million for Q1 2026 at Aurinia Pharmaceuticals, up from $639.6 million in the prior quarter.
• Across five years, Assets Average topped out at $737.8 million in Q1 2026 and bottomed at $461.3 million in Q1 2023.
• A 5-year average of $536.0 million and a median of $525.1 million in 2022 frame the typical range for Assets Average.
• Annual changes were most pronounced in 2023 — Assets Average retreated 12.15% — and 2026, when it surged 39.8%.
• Aurinia Pharmaceuticals' Assets Average stood at $479.6 million in 2022, then rose by 15.01% to $551.5 million in 2023, then declined by 0.28% to $550.0 million in 2024, then gained by 16.28% to $639.6 million in 2025, then climbed by 15.36% to $737.8 million in 2026.
• Business Quant data shows AUPH's Assets Average at $737.8 million in Q1 2026, $639.6 million in Q4 2025, and $515.0 million in Q3 2025.